ArticleArthritis care & research2026

Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drug.

Fenglong Xie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.